NPS Pharmaceuticals Inc said it acquired development rights to two experimental compounds for the treatment of a rare endocrine disorder after it amended its earlier agreement with GlaxoSmithKline Plc . The new agreement replaces a prior license agreement between NPS and GSK from 1993. Under the deal, NPS will get development rights to two compounds, SB-423557 and SB-423562, for the treatment of autosomal dominant hypocalcemia with hypercalciuria (ADHH) -- a rare disorder involving increased calcium receptor activity.
